Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03800134 · ClinicalTrials.gov registry record · Phase 3
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 825
- Enrollment target
- 20
- Study locations
NCT03800134 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 825 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT03800134, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 825 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- OTHER Placebo
- DRUG Pemetrexed
- DRUG Durvalumab
Study Locations (20)
New York
- Research Site - New York
- Research Site - New York
- Research Site - Shirley
California
- Research Site - Duarte
- Research Site - Orange
Florida
- Research Site - Boca Raton
- Research Site - Jacksonville
Kentucky
- Research Site - Ashland
- Research Site - Lexington
Maryland
- Research Site - Silver Spring
- Research Site - Towson
Minnesota
- Research Site - Duluth
- Research Site - Minneapolis
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2028-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03800134
The ClinicalTrials.gov registry entry for NCT03800134 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 825 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (26% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03800134 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03800134 about?
NCT03800134 is a clinical study titled "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer". This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
What is the current status of trial NCT03800134?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2018-12-06. Estimated completion is 2028-09-11.
What conditions does trial NCT03800134 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03800134?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Placebo (OTHER), Pemetrexed (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03800134?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03800134 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.